Literature DB >> 33096365

A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.

Stephen Parkin1, Joanne Neale2, Caral Brown3, Jermaine D Jones4, Laura Brandt4, Felipe Castillo4, Aimee N C Campbell4, John Strang5, Sandra D Comer4.   

Abstract

BACKGROUND: Take-home naloxone (THN) kits have been designed to provide community members (including people who use drugs, their families and/or significant others) with the necessary resources to address out-of-hospital opioid overdose events. Kits typically include two doses of naloxone. This 'twin-pack' format means that lay responders need information on how to use each dose. Advice given tends to be based on dosage algorithms used by medical personnel. However, little is currently known about how and why people who use drugs, acting as lay responders, decide to administer the second dose contained within single THN kits. The aim of this article is to explore this issue.
METHODS: Data were generated from a qualitative semi-structured interview study that was embedded within a randomised controlled trial examining the risks and benefits of Overdose Education and Naloxone Distribution (OEND) training in New York City (NYC). Analysis for this article focuses upon the experiences of 22 people who use(d) opioids and who provided repeat naloxone administrations (RNA) during 24 separate overdose events. The framework method of analysis was used to compare the time participants believed had passed between each naloxone dose administered ('subjective response interval') with the 'recommended response interval' (2-4 minutes) given during OEND training. Framework analysis also charted the various reasons and rationale for providing RNA during overdose interventions.
RESULTS: When participants' subjective response intervals were compared with the recommended response interval for naloxone dosing, three different time periods were reported for the 24 overdose events: i. 'two doses administered in under 2 minutes' (n = 10); ii. 'two doses administered within 2-4 minutes' (n = 7), and iii. 'two doses administered more than 4 minutes apart' (n = 7). A variety of reasons were identified for providing RNA within each of the three categories of response interval. Collectively, reasons for RNA included panic, recognition of urgency, delays in retrieving naloxone kit, perceptions of recipients' responsiveness/non-responsiveness to naloxone, and avoidance of Emergency Response Teams (ERT).
CONCLUSION: Findings suggest that decision-making processes by people who use opioids regarding how and when to provide RNA are influenced by factors that relate to the emergency event. In addition, the majority of RNA (17/24) occurred outside of the recommended response interval taught during OEND training. These findings are discussed in terms of evidence-based intervention and 'evidence-making intervention' with suggestions for how RNA guidance may be developed and included within future/existing models of OEND training.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Framework analysis; Harm Reduction; Naloxone response intervals; New York City; People who use opioids; Repeat naloxone administrations; Take home naloxone

Mesh:

Substances:

Year:  2020        PMID: 33096365      PMCID: PMC7940548          DOI: 10.1016/j.drugpo.2020.102968

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  38 in total

1.  Emergency naloxone for heroin overdose.

Authors:  John Strang; Michael Kelleher; David Best; Soraya Mayet; Victoria Manning
Journal:  BMJ       Date:  2006-09-23

2.  Evidence-making interventions in health: A conceptual framing.

Authors:  Tim Rhodes; Kari Lancaster
Journal:  Soc Sci Med       Date:  2019-08-10       Impact factor: 4.634

3.  The Role of Science in Addressing the Opioid Crisis.

Authors:  Nora D Volkow; Francis S Collins
Journal:  N Engl J Med       Date:  2017-05-31       Impact factor: 91.245

4.  Emergency epinephrine use for food allergy reactions in Chicago Public Schools.

Authors:  Lilliana DeSantiago-Cardenas; Victoria Rivkina; Stephanie A Whyte; Blair C Harvey-Gintoft; Bryan J Bunning; Ruchi S Gupta
Journal:  Am J Prev Med       Date:  2014-10-23       Impact factor: 5.043

5.  "I felt like a superhero": the experience of responding to drug overdose among individuals trained in overdose prevention.

Authors:  Karla D Wagner; Peter J Davidson; Ellen Iverson; Rachel Washburn; Emily Burke; Alex H Kral; Miles McNeeley; Jennifer Jackson Bloom; Stephen E Lankenau
Journal:  Int J Drug Policy       Date:  2013-08-09

6.  Higher naloxone dosing may be required for opioid overdose.

Authors:  Russell Bardsley
Journal:  Am J Health Syst Pharm       Date:  2019-10-30       Impact factor: 2.637

7.  Opiate users' knowledge about overdose prevention and naloxone in New York City: a focus group study.

Authors:  Nancy Worthington; Tinka Markham Piper; Sandro Galea; David Rosenthal
Journal:  Harm Reduct J       Date:  2006-07-05

Review 8.  Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine.

Authors:  John Strang; Rebecca McDonald; Gabrielle Campbell; Louisa Degenhardt; Suzanne Nielsen; Alison Ritter; Ola Dale
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

9.  Distortions of subjective time perception within and across senses.

Authors:  Virginie van Wassenhove; Dean V Buonomano; Shinsuke Shimojo; Ladan Shams
Journal:  PLoS One       Date:  2008-01-16       Impact factor: 3.240

10.  A conceptual framework for implementation fidelity.

Authors:  Christopher Carroll; Malcolm Patterson; Stephen Wood; Andrew Booth; Jo Rick; Shashi Balain
Journal:  Implement Sci       Date:  2007-11-30       Impact factor: 7.327

View more
  1 in total

1.  Emotional reactions of trained overdose responders who use opioids following intervention in an overdose event.

Authors:  Laura Brandt; Aimee N C Campbell; Jermaine D Jones; Suky Martinez; Joanne Neale; Stephen Parkin; Caral Brown; John Strang; Sandra D Comer
Journal:  Subst Abus       Date:  2021-09-14       Impact factor: 3.716

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.